About Us
Our Company Overview
Our Vision
To be a leading global group to capture and deliver the maximum potential of Biotherapeutics, related to treatment and cure solutions for various cancers at an affordable cost.
Our Mission
To develop novel antibodies and affordable biosimilars for the treatment of cancers and immunological diseases by advancing our groundbreaking research and commercializing outreach.
Our Focus Area
MetaGen Biologics specializes in biologics for oncology, immunology and other therapeutic segments.
MetaGen Biologics was founded with two divisions:
Biosimilars Division
We are working towards our goal of having a niche biosimilar portfolio in the ASEAN region for monoclonal antibodies, to address the unmet needs of accessibility.
Novel Biologics Division
Development of innovative platform technologies with a focus on oncology medicines for multiple targets.
Meet The Team
Leadership Team
(Pending Employment Contracts To Be Executed)
Lim Kah Meng, PhD
Founder, Chief Executive Officer
Lim Kah Meng, PhD
Founder, Chief Executive Officer
Dr Lim Kah Meng has dedicated a large part of his research focus on molecular biomedicine. For more than 20 years, he fervently pursued his scientific interests on bioactive molecules that govern and regulate cellular pathways leading to cellular homeostasis and wellbeing. Being credited as the “Father of Molecular Edible Birds Nests”, Dr Lim has filed multiple patents on the extraction processes for the bioactive molecules including immunological active bio-molecules from edible bird nests.
Dr. Lim is also known in this region to be the “Father of Molecular Placenta” where he has successfully developed highly popular products for the commercial world based on placental stem cell extracts.
He has since diversified into stem cell research including products or platforms based on induced pluripotent stem cells for personalized aesthetic and therapeutic for acute illnesses such as diabetes, psoriasis and dementia. Dr. Lim has also published a paper documenting successful clinical cases for 9 cancer patients in Singapore using high done intravenous vitamin C.
On biologics research, Dr Lim has at least a few years of precious experience; working with leading global biologics experts both at Agency for Science, Technology and Research (A*STAR) [Singapore] as well as at University of Minnesota [USA].
Dr Lim is also deep into biomedical research for neuroscience. He has filed for at least 5 patents related to cannabinoids, specifically on medical cannabis but not exclusive to just neurological functions, optimizing bioactive compounds, Dr. Lim’s most recent research is in successfully using micro RNAs as the next generation diagnostic markers for most cancer and chronic diseases detection. Dr Lim was also the recipient for the Singapore award of the 10 outstanding young persons of the world in 2012.
Dr. Lim joined the Singapore PainCare Holdings Ltd as an independent Non-Executive Director in March 2021 and at the same time, serves as an Honorary Advisor of the World LIN Chamber of Commerce, Singapore.
Advisory Board
(Pending Advisory Agreements To Be Executed)
Novanne Seah
Pharmaceutical branding and packaging
Our Partners
